BridgeBio Pharma (BBIO)
(Delayed Data from NSDQ)
$27.85 USD
+3.23 (13.12%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $27.78 -0.07 (-0.25%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
BridgeBio Pharma (BBIO) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$48.77 | $70.00 | $37.00 | 75.12% |
Price Target
Based on short-term price targets offered by 13 analysts, the average price target for BridgeBio Pharma comes to $48.77. The forecasts range from a low of $37.00 to a high of $70.00. The average price target represents an increase of 75.12% from the last closing price of $27.85.
Analyst Price Targets (13)
Broker Rating
BridgeBio Pharma currently has an average brokerage recommendation (ABR) of 1.21 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 14 brokerage firms. The current ABR compares to an ABR of 1.21 a month ago based on 14 recommendations.
Of the 14 recommendations deriving the current ABR, 12 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 85.71% and 7.14% of all recommendations. A month ago, Strong Buy made up 85.71%, while Buy represented 7.14%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/BBIO.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 12 | 12 | 12 | 12 | 12 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.21 | 1.21 | 1.21 | 1.21 | 1.21 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/1/2024 | Cantor Fitzgerald & Co | Josh Schimmer | Strong Buy | Strong Buy |
6/5/2024 | H.C. Wainwright & Co. | Raghuram Selvaraju | Strong Buy | Strong Buy |
5/28/2024 | UBS | Eliana Merle | Not Available | Strong Buy |
5/13/2024 | Evercore Partners | Cory Kasimov | Not Available | Strong Buy |
5/3/2024 | SVB Securities | Mani Foroohar | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Tyler Van Buren | Strong Buy | Strong Buy |
3/21/2024 | Raymond James | Danielle Brill | Moderate Buy | Moderate Buy |
3/11/2024 | Goldman Sachs | Paul K Choi | Strong Buy | Strong Buy |
3/4/2024 | Mizuho SecuritiesUSA | Salim Syed | Strong Buy | Strong Buy |
2/23/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
1/31/2024 | BMO Capital Markets | Kostas Biliouris | Not Available | Hold |
12/8/2023 | Wells Fargo Securities | Tiago Fauth | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.21 |
ABR (Last week) | 1.21 |
# of Recs in ABR | 14 |
Average Target Price | $48.77 |
LT Growth Rate | 26.80% |
Industry | Medical - Generic Drugs |
Industry Rank by ABR | 53 of 253 |
Current Quarter EPS Est: | -1.02 |